Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...

The Food and Drug Administration has granted Fast Track designation to bempikibart for the treatment of alopecia areata.

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

has granted Fast Track designation to bempikibart for the treatment of Alopecia Areata (AA), an autoimmune disease that attacks hair follicles causing patchy hair loss. Fast Track is a process ...

About 700,000 people in the United States live with alopecia areata 1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing ...

Results showed bempikibart reduced the mean SALT score by 16% vs 2% with placebo at week 24. The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the ...

April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...